Norgine Completes Acquisition of Theravia to Expand Rare Disease Portfolio

Norgine, a specialized pharmaceutical company, has successfully completed the acquisition of Theravia, an international pharmaceutical firm known for its therapies targeting rare and debilitating diseases. This milestone is seen as a significant development in Norgine's mission to provide life-changing medicines for patients with high unmet medical needs. The acquisition will allow Norgine to integrate and expand its operations, systems, and teams, further bolstering its portfolio in the field of rare diseases. According to Janneke van der Kamp, CEO of Norgine, this addition enhances the company's expertise and supports its growth strategy focused on expanding the market for products in Europe and New Zealand, particularly in areas with significant medical needs. Post-acquisition, Theravia is set to operate as a Norgine affiliate. Norgine boasts annual revenues exceeding 550 million euros and a track record of over 120 years in delivering transformational products to patients across Western Europe, Australia, and New Zealand. The company's integrated approach, marked by robust commercial capabilities, deep medical and regulatory expertise, internal manufacturing, strong supply networks, and top-tier enabling functions, positions it to rapidly deliver high-quality medicines to over 25 million patients annually. The acquisition aligns with Norgine's commitment to operational excellence and therapeutic innovation.